Navigation Links
Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP
Date:11/21/2007

SOUTH SAN FRANCISCO, Calif., Nov. 21 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will host a conference call with simultaneous webcast to discuss the results of its Phase 2 clinical study of R788, a novel, oral Syk kinase inhibitor, in patients with Immune Thrombocytopenic Purpura (ITP) on Tuesday, December 4, 2007 at 4:30pm E.S.T. Participating on the call will be Rigel senior management and the principal investigator on the study, James B. Bussel, M.D., director of the Platelet Research and Treatment program at the Phyllis and David Komansky Center for Children's Health and NewYork-Presbyterian Hospital/Weill Cornell Medical Center and professor of pediatrics in obstetrics and gynecology and in medicine at the Weill Cornell Medical College. In addition, Rigel will be presenting a poster on R788 in ITP at the ASH meeting on December 8, 2007, from 9:00a.m. - 7:30p.m., in Atlanta, GA.

Conference Call Details

To access the live call, please dial 866-831-6267 (domestic) or 617-213-8857 (international) 10 minutes prior to the start time and use the passcode 14390209. A replay of the call will be available at approximately 3:30p.m. PST on December 4, 2007 until December 11, 2007. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and use the passcode 91472601.

The conference call will also be webcast live and can be accessed from Rigel's website at http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary. A replay of the conference call will b
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Rigel Announces Third Quarter 2007 Financial Results
2. Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
3. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
4. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
5. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
6. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
7. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
8. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
9. AtriCure to Present at Roth Capital Partners 2007 New York Conference
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. MDS to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... to prevent Ebola virus disease will begin next week ... (NIAID), part of the National Institutes of Health. , ... a vaccine co-developed by NIAID and GlaxoSmithKline (GSK) and ... generate an immune system response in healthy adults. Testing ... Bethesda, Maryland. , The study is the first of ...
(Date:8/28/2014)... patients in the study who were on a class ... them as prescribed in the first six months. Patients ... hospitals around the UK involved in the study. , ... and Genomics at The University of Manchester, who led ... correctly, known as ,non-adherence, reduced their effectiveness and may ...
(Date:8/28/2014)... AmeriPride Services, a leading textile services and supply ... its new Customer Portal, an online resource that makes ... for customers. The industry-leading digital tool allows customers to ... company. , Features of the new customer portal include ... and pay bills online , View delivery ...
(Date:8/28/2014)... 2014 Clarity PSO , an ... as a federal Patient Safety Organization (PSO) for another ... Healthcare Research and Quality (AHRQ). Clarity PSO will continue ... services following the true intentions of the Patient Safety ... are proud and eager to continue our journey as ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Genetic ... available throughout the world, with large reference laboratories ... Since laboratories differ with regard to the genetic ... costs, payers may struggle to find the most ... To help clients sort through these differences, Hayes, ...
Breaking Medicine News(10 mins):Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5Health News:Arthritis patients failing to take expensive medication, according to new research 2Health News:AmeriPride Services Launches New Customer Portal 2Health News:AmeriPride Services Launches New Customer Portal 3Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 2Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 3Health News:Hayes, Inc. Unveils Laboratory Comparison Tables for GTE Clients 2
... Parents of children with allergies are prone to increased ... ,According to foodconsumer.org, children of parents who ... according to a new study by researchers at Cincinnati ... for allergies are twice as likely to snore. ...
... study conducted on 2500 patients has suggested that women who ... dementia. A Mayo Clinic, Minnesota team has revealed that young ... the age of 38, face a risk enhanced by 260%. ... Neurology. ,Researchers have zeroed in on the possible reason ...
... friend who was a colleague of the murdered nurse, Cheryl Moss ... killed. //When speaking to the press outside the St George's Hospital ... on the Canvey ward. She said that Cheryl was desperate to ... that one among them was murdered in the common smoking spot. ...
... is a genetic disorder that affects the heart's largest artery, ... bottom of the disease and researchers at Johns Hopkins University// ... the blood-pressure drug that has shown promise in recent studies ... Hopkins University said that the Merck's drug appears to prevent ...
... to the fumes of solvents used in house renovations.Contact ... give rise to allergies in young children, said Norbert ... ,Pregnant women should leave renovation work to ... the work area altogether. ,'It is also ...
... culling of poultry began in Niger one of the world’s ... an outbreak of deadly// avian flu near its southern border ... culling of all poultry in affected areas on February 28, ... has now appealed for international help, as it lacked the ...
Cached Medicine News:Health News:Children Of Snoring Parents Are More Likely To Inherit Themselves 2Health News:Cognitive Impairment or Dementia Risk, Pronounced with Ovary loss 2Health News:Delayed Start By Niger On Culling Of Poultry 2Health News:Delayed Start By Niger On Culling Of Poultry 3
(Date:8/28/2014)... , Aug. 28, 2014  Sequent Medical, ... enrollment in an Investigational Device Exemption ("IDE") pivotal ... the WEB™ Aneurysm Embolization System ("WEB"). Adam ... Department of Neurosurgery/Semmes-Murphey Clinic and Principal Investigator of ... the study, treating them with the WEB at ...
(Date:8/28/2014)... 28, 2014 GenSpera, Inc. (OTCQB: GNSZ), a ... cancer, announces the recent publication of the article "Targeting ... The recent article co-authored by Doan, et ... of GenSpera,s prodrug technology platform that is designed to ... plant Thapsia garganica ) directly to tumors. These ...
(Date:8/28/2014)... , Aug. 28, 2014 Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm), announced today ... of cGMP manufacturing of SYN-004, Synthetic Biologics, proprietary ... Clostridium difficile ( C. difficile ) infections. ...
Breaking Medicine Technology:Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 2Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 3GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 2Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 3Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 4Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 5
... TRACON Pharmaceuticals, a biotechnology company that develops targeted ... Phase 1 clinical results from studies of TRC105 and ... at the American Society of Clinical Oncology annual meeting ... programs target unique pathways with the potential for broad ...
... Ascenta Therapeutics announced today that eleven presentations or publications ... pan-Bcl-2 inhibitor, in several major tumor types will be ... (ASCO) Annual Meeting, May 29-June 2, in Orlando, Florida. ... .(Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO ...
Cached Medicine Technology:TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 3
... The Isoseeds I-125 are brachytherapy sources which ... of localized tumors, especially in the prostate. ... the conclusion of the therapeutic effect, i.e. ... are intended for single use. They are ...
... Four 64 mirrors for complete ... lens rotation. Directly hand held for ... or small holding ring. Small diameter ... gonioscopy without methylcellulose. Advanced technology, multi-layer ...
... Three mirrors of 64, ... small diameter contact surface for ... can be viewed through the ... Multi-layer polymer coating protects mirrors ...
West lacrimal cannula blunt tip with side port....
Medicine Products: